Valuation : Immatics N.V.

Market Cap 120.15Cr 103.61Cr 98Cr 89Cr 166.64Cr 11TCr 167.62Cr 1.16TCr 447.37Cr 5.83TCr 451.23Cr 441.26Cr 18TCr P/E 2026 *
-4.16x
P/E 2027 * -4.18x
Enterprise Value 92Cr 79Cr 75Cr 68Cr 126.94Cr 8.74TCr 127.69Cr 886.43Cr 340.81Cr 4.44TCr 343.75Cr 336.16Cr 14TCr EV / Sales 2026 *
19.7x
EV / Sales 2027 * 21.8x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week-8.05%
Current month-7.76%
1 month-9.85%
3 months-2.98%
6 months-12.36%
Current year-16.29%
1 week 8.54
Extreme 8.535
9.56
1 month 8.4
Extreme 8.4
9.98
Current year 8.17
Extreme 8.17
11.94
1 year 5.67
Extreme 5.67
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
15.02
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 8,63,060 0.6436%
18/03/26 Other

Chief Financial Officer

3,50,000 0.2611%
18/03/26 Other

Head of Human Resources

2,11,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%-8.05%+48.48%-29.34% 120.15Cr
-2.11%-1.68%+44.52%+95.15% 6.69TCr
-0.23%-4.45%+30.39%+73.64% 6.2TCr
+1.67%+2.47%-11.23%+388.34% 2.83TCr
-1.05%-4.43%+30.56%+10.07% 2.46TCr
+0.34%-6.78%-7.27%-17.99% 2.43TCr
+0.43%-3.37%+14.85%-19.29% 1.94TCr
-3.03%-2.29%+185.12%+334.07% 1.68TCr
-1.94%-4.94%-5.29%+495.65% 1.42TCr
-2.28%-4.90%+43.64%+155.21% 1.39TCr
Average -0.77%-3.92%+37.38%+148.55% 2.72TCr
Weighted average by Cap. -0.84%-3.08%+33.53%+132.95%

Financials

2026 *2027 *
Net sales 4.65Cr 4.01Cr 3.8Cr 3.44Cr 6.45Cr 444.63Cr 6.49Cr 45Cr 17Cr 225.97Cr 17Cr 17Cr 714.62Cr 3.96Cr 3.41Cr 3.23Cr 2.93Cr 5.49Cr 378.16Cr 5.52Cr 38Cr 15Cr 192.19Cr 15Cr 15Cr 607.79Cr
Net income -29Cr -25Cr -23Cr -21Cr -40Cr -2.75TCr -40Cr -278.33Cr -107.01Cr -1.4TCr -107.93Cr -105.55Cr -4.41TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.96TCr -43Cr -299.87Cr -115.29Cr -1.5TCr -116.28Cr -113.72Cr -4.75TCr
Net Debt -29Cr -25Cr -23Cr -21Cr -40Cr -2.73TCr -40Cr -277.16Cr -106.56Cr -1.39TCr -107.48Cr -105.11Cr -4.39TCr -34Cr -29Cr -28Cr -25Cr -47Cr -3.24TCr -47Cr -328.01Cr -126.11Cr -1.64TCr -127.2Cr -124.39Cr -5.2TCr
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
11/26/11 $8.790 +0.46% 5,27,249
10/26/10 $8.750 -3.95% 7,98,772
09/26/09 $9.110 -3.50% 3,26,082
08/26/08 $9.440 -1.26% 6,99,515
04/26/04 $9.560 +1.06% 4,97,160
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.790USD
Average target price
17.63USD
Spread / Average Target
+100.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!